Research ExplorerPublicationsThe Combination of DNA Ploidy Status and PTEN/6q15 Deletions...

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

Standard

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. / Lennartz, Maximilian; Minner, Sarah; Brasch, Sophie ; Wittmann, Hilko ; Paterna, Leonard ; Angermeier, Katja; Öztürk, Eray ; Shihada, Rami ; Ruge, Mingu ; Kluth, Martina; Koop, Christina; Wilczak, Waldemar; Krech, Till; Lebok, Patrick; Wittmer, Corinna; Heinzer, Hans; Steuber, Thomas; Adam, Meike; Huland, Hartwig; Graefen, Markus; Haese, Alexander; Simon, Ronald; Sauter, Guido; Schlomm, Thorsten.

In: CLIN CANCER RES, Vol. 22, No. 11, 01.06.2016, p. 2802-11.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lennartz, M, Minner, S, Brasch, S, Wittmann, H, Paterna, L, Angermeier, K, Öztürk, E, Shihada, R, Ruge, M, Kluth, M, Koop, C, Wilczak, W, Krech, T, Lebok, P, Wittmer, C, Heinzer, H, Steuber, T, Adam, M, Huland, H, Graefen, M, Haese, A, Simon, R, Sauter, G & Schlomm, T 2016, 'The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer', CLIN CANCER RES, vol. 22, no. 11, pp. 2802-11. https://doi.org/10.1158/1078-0432.CCR-15-0635

APA

Lennartz, M., Minner, S., Brasch, S., Wittmann, H., Paterna, L., Angermeier, K., Öztürk, E., Shihada, R., Ruge, M., Kluth, M., Koop, C., Wilczak, W., Krech, T., Lebok, P., Wittmer, C., Heinzer, H., Steuber, T., Adam, M., Huland, H., ... Schlomm, T. (2016). The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. CLIN CANCER RES, 22(11), 2802-11. https://doi.org/10.1158/1078-0432.CCR-15-0635

Vancouver

Lennartz M, Minner S, Brasch S, Wittmann H, Paterna L, Angermeier K et al. The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. CLIN CANCER RES. 2016 Jun 1;22(11):2802-11. https://doi.org/10.1158/1078-0432.CCR-15-0635

Bibtex

@article{24cd8dca47a349a1a3fdef4448b0d6f9,
title = "The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer",
abstract = "PURPOSE: Aberrant DNA content has been discussed as a potential prognostic feature in prostate cancer.EXPERIMENTAL DESIGN: We analyzed the clinical significance of DNA ploidy in combination with prognostic relevant deletions of PTEN and 6q15 in 3,845 prostate cancers.RESULT: The DNA status was diploid in 67.8%, tetraploid in 25.6%, and aneuploid in 6.8% of tumors, and deletions of PTEN and 6q15 occurred in 17.8% and 20.3% of tumors. Abnormal DNA content and deletions were linked to high Gleason score, advanced tumor stage, and positive nodal stage (P < 0.0001 each). The risk of PSA recurrence increased from diploid to tetraploid and from tetraploid to aneuploid DNA status (P < 0.0001 each). However, 40% of patients with Gleason score ≥4+4 and 55% of patients with PSA recurrence had diploid cancers. This fraction decreased to 21% (Gleason ≥4+4) and 29% (PSA recurrence) if PTEN and/or 6q deletion data were added to ploidy data to identify cancers with an aberrant DNA status. The significance of combining both deletions and ploidy was further demonstrated in a combined recurrence analysis. Presence of deletions increased the risk of PSA recurrence in diploid (P < 0.0001), tetraploid (P < 0.0001), and aneuploid cancers (P = 0.0049), and the combination of ploidy data and deletions provided clinically relevant information beyond the CAPRA-S nomogram. Multivariate modeling including preoperatively and postoperatively available parameters identified the {"}combined DNA status{"} as a strong independent predictor of poor patient outcome.CONCLUSIONS: The combinatorial DNA content analysis involving general (ploidy) and specific events (deletions) has the potential for clinical utility in prostate cancer. Clin Cancer Res; 22(11); 2802-11. {\textcopyright}2016 AACR.",
keywords = "Journal Article",
author = "Maximilian Lennartz and Sarah Minner and Sophie Brasch and Hilko Wittmann and Leonard Paterna and Katja Angermeier and Eray {\"O}zt{\"u}rk and Rami Shihada and Mingu Ruge and Martina Kluth and Christina Koop and Waldemar Wilczak and Till Krech and Patrick Lebok and Corinna Wittmer and Hans Heinzer and Thomas Steuber and Meike Adam and Hartwig Huland and Markus Graefen and Alexander Haese and Ronald Simon and Guido Sauter and Thorsten Schlomm",
note = "{\textcopyright}2016 American Association for Cancer Research.",
year = "2016",
month = jun,
day = "1",
doi = "10.1158/1078-0432.CCR-15-0635",
language = "English",
volume = "22",
pages = "2802--11",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

AU - Lennartz, Maximilian

AU - Minner, Sarah

AU - Brasch, Sophie

AU - Wittmann, Hilko

AU - Paterna, Leonard

AU - Angermeier, Katja

AU - Öztürk, Eray

AU - Shihada, Rami

AU - Ruge, Mingu

AU - Kluth, Martina

AU - Koop, Christina

AU - Wilczak, Waldemar

AU - Krech, Till

AU - Lebok, Patrick

AU - Wittmer, Corinna

AU - Heinzer, Hans

AU - Steuber, Thomas

AU - Adam, Meike

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Haese, Alexander

AU - Simon, Ronald

AU - Sauter, Guido

AU - Schlomm, Thorsten

N1 - ©2016 American Association for Cancer Research.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - PURPOSE: Aberrant DNA content has been discussed as a potential prognostic feature in prostate cancer.EXPERIMENTAL DESIGN: We analyzed the clinical significance of DNA ploidy in combination with prognostic relevant deletions of PTEN and 6q15 in 3,845 prostate cancers.RESULT: The DNA status was diploid in 67.8%, tetraploid in 25.6%, and aneuploid in 6.8% of tumors, and deletions of PTEN and 6q15 occurred in 17.8% and 20.3% of tumors. Abnormal DNA content and deletions were linked to high Gleason score, advanced tumor stage, and positive nodal stage (P < 0.0001 each). The risk of PSA recurrence increased from diploid to tetraploid and from tetraploid to aneuploid DNA status (P < 0.0001 each). However, 40% of patients with Gleason score ≥4+4 and 55% of patients with PSA recurrence had diploid cancers. This fraction decreased to 21% (Gleason ≥4+4) and 29% (PSA recurrence) if PTEN and/or 6q deletion data were added to ploidy data to identify cancers with an aberrant DNA status. The significance of combining both deletions and ploidy was further demonstrated in a combined recurrence analysis. Presence of deletions increased the risk of PSA recurrence in diploid (P < 0.0001), tetraploid (P < 0.0001), and aneuploid cancers (P = 0.0049), and the combination of ploidy data and deletions provided clinically relevant information beyond the CAPRA-S nomogram. Multivariate modeling including preoperatively and postoperatively available parameters identified the "combined DNA status" as a strong independent predictor of poor patient outcome.CONCLUSIONS: The combinatorial DNA content analysis involving general (ploidy) and specific events (deletions) has the potential for clinical utility in prostate cancer. Clin Cancer Res; 22(11); 2802-11. ©2016 AACR.

AB - PURPOSE: Aberrant DNA content has been discussed as a potential prognostic feature in prostate cancer.EXPERIMENTAL DESIGN: We analyzed the clinical significance of DNA ploidy in combination with prognostic relevant deletions of PTEN and 6q15 in 3,845 prostate cancers.RESULT: The DNA status was diploid in 67.8%, tetraploid in 25.6%, and aneuploid in 6.8% of tumors, and deletions of PTEN and 6q15 occurred in 17.8% and 20.3% of tumors. Abnormal DNA content and deletions were linked to high Gleason score, advanced tumor stage, and positive nodal stage (P < 0.0001 each). The risk of PSA recurrence increased from diploid to tetraploid and from tetraploid to aneuploid DNA status (P < 0.0001 each). However, 40% of patients with Gleason score ≥4+4 and 55% of patients with PSA recurrence had diploid cancers. This fraction decreased to 21% (Gleason ≥4+4) and 29% (PSA recurrence) if PTEN and/or 6q deletion data were added to ploidy data to identify cancers with an aberrant DNA status. The significance of combining both deletions and ploidy was further demonstrated in a combined recurrence analysis. Presence of deletions increased the risk of PSA recurrence in diploid (P < 0.0001), tetraploid (P < 0.0001), and aneuploid cancers (P = 0.0049), and the combination of ploidy data and deletions provided clinically relevant information beyond the CAPRA-S nomogram. Multivariate modeling including preoperatively and postoperatively available parameters identified the "combined DNA status" as a strong independent predictor of poor patient outcome.CONCLUSIONS: The combinatorial DNA content analysis involving general (ploidy) and specific events (deletions) has the potential for clinical utility in prostate cancer. Clin Cancer Res; 22(11); 2802-11. ©2016 AACR.

KW - Journal Article

U2 - 10.1158/1078-0432.CCR-15-0635

DO - 10.1158/1078-0432.CCR-15-0635

M3 - SCORING: Journal article

C2 - 26813356

VL - 22

SP - 2802

EP - 2811

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 11

ER -